Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Biliary Tract Cancer
Phase 2a MyPathway Results of Pertuzumab plus Trastuzumab for the Treatment of HER2-Positive Metastatic Biliary Tract Cancer
Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
— December 17, 2021
Results of an ongoing, phase 2a, multiple-basket study (MyPathway) showed that dual
HER2
-targeted therapy with pertuzumab plus trastuzumab was well-tolerated in patients with previously treated
HER2
-positive metastatic biliary tract cancer.
Read More
Zanidatamab (ZW25) in HER2-Positive Biliary Tract Cancers: Results from a Phase 1 Study
Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
— December 17, 2021
Results from a first-in-human, phase 1 study have shown that the bispecific
HER2
-targeted antibody zanidatamab is well-tolerated and has antitumor activity in patients with
HER2
-overexpressing biliary tract cancers.
Read More
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Biliary Tract Cancers in the Multicohort Phase 2 LEAP-005 Study
Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
— December 17, 2021
Results of the phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab shows promising antitumor activity and manageable toxicity in previously treated patients with advanced biliary tract cancers.
Read More
A Phase 1/2 Study of the Safety and Efficacy of the Arginase Inhibitor INCB001158 plus Chemotherapy in Patients with Advanced Biliary Tract Cancer
Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
— December 17, 2021
Results of an open-label, phase 1/2 study indicate that addition of INCB001158 to the standard gemcitabine/cisplatin backbone was tolerable, did not result in significant additional toxicity, and showed modest clinical activity in the biliary tract cancers cohort.
Read More
First-Line Immunotherapy plus Chemotherapy Significantly Improves Survival in Advanced Biliary Tract Cancer
Biliary Tract Cancer
Web Exclusives
— October 28, 2021
On October 25, 2021, AstraZeneca announced high-level positive results from the phase 3 clinical trial TOPAZ-1, demonstrating that adding the immunotherapy durvalumab (Imfinzi) to first-line standard-of-care chemotherapy leads to a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone in patients with advanced biliary tract cancer.
Read More
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
ASCO Highlights
,
Cholangiocarcinoma
,
Biliary Tract Cancer
September/October 2021, Vol 2, No 3
— October 7, 2021
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and
FGFR2
fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.
Read More
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
ASCO Highlights
,
Biliary Tract Cancer
,
Cholangiocarcinoma
,
Pancreatic Cancer
March 2021, Vol 2, No 1
— April 13, 2021
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
Read More
Zanidatamab Addresses an Unmet Need in Patients with HER2-Amplified Biliary Tract Cancer
Biliary Tract Cancer
,
CCA Summit 2020 Highlights
,
Summit Posters
December 2020, Vol 1, No 3
— January 5, 2021
Patients with relapsed or refractory HER2-amplified biliary tract cancer have few treatment options after first-line therapy. Shubham Pant, MD, Associate Professor, Gastrointestinal Oncology, M.D. Anderson Cancer Center, Houston, TX, presented the results of a phase 1 clinical trial he and his colleagues conducted. The study examined the safety and antitumor activity of zanidatamab, a bispecific (ie, binding to 2 distinct sites on the
HER2
receptor)
HER2
-targeted antibody. The unique antibody geometry of zanidatamab enables it to activate several mechanisms of action after binding to the
HER2
receptor.
Read More
Telotristat Ethyl and First-Line Chemotherapy Combination Investigated for Advanced Biliary Tract Cancer
Biliary Tract Cancer
,
CCA Summit 2020 Highlights
,
Summit Posters
December 2020, Vol 1, No 3
— January 5, 2021
The metabolism of serotonin is dysregulated in cholangiocarcinoma (CCA) cell lines compared with normal cholangiocytes and in tissue and bile from patients with CCA.1 Telotristat ethyl (Xermelo) is a tryptophan hydroxylase inhibitor that is indicated for the treatment of patients with carcinoid syndrome–related diarrhea not well-controlled by somatostatin analog. Telotristat ethyl is currently being investigated for the treatment of patients with biliary tract cancer, including CCA tumors that express serotonin.
Read More
The Khorana Score Not Predictive of Thrombotic Events in Patients with Biliary Tract Cancer
Biliary Tract Cancer
,
CCA Summit 2020 Highlights
,
Summit Posters
December 2020, Vol 1, No 3
— January 5, 2021
Cancer-related venous thromboembolism (VTE) is a significant cause of morbidity and mortality. There is a paucity of studies characterizing VTE in patients with biliary tract cancer; however, a few retrospective analyses suggest an incidence of VTE of up to 23%.
Read More
Page 2 of 4
1
2
3
4
View the Latest Issue of CCA News
Read Issue
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
CCA News
Print Edition
CCA News
Weekly e‑Newsletter
-- Please Select Country --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
CCA News
's
Privacy Policy
, and
CCA News
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION